ANDA 40321, held by Actavis Elizabeth. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 40321 (Methylphenidate Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Feb 5, 2002, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 5, 2002 | Original application | Approved |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters